TransMedics (TMDX) Equity Average (2018 - 2026)

TransMedics' Equity Average history runs 9 years deep, the most recent figure standing at $483.6 million for Q1 2026.

• In Q1 2026, Equity Average rose 95.41% year-over-year to $483.6 million; the TTM figure through Mar 2026 stood at $483.6 million (up 95.41% YoY), while the FY2025 annual figure was $350.9 million, up 91.82% from the prior year.
• Equity Average was $483.6 million for Q1 2026 at TransMedics, up from $414.2 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $483.6 million in Q1 2026 to a low of $55.4 million in Q2 2022.
• Historically, Equity Average has averaged $209.9 million across 5 years, with a median of $187.6 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Equity Average plunged 40.62% in 2022, then soared 204.83% in 2023.
• A 5-year view of Equity Average shows it stood at $187.6 million in 2022, then fell by 29.73% to $131.8 million in 2023, then soared by 66.32% to $219.3 million in 2024, then surged by 88.88% to $414.2 million in 2025, then gained by 16.76% to $483.6 million in 2026.
• The last three Equity Average figures came in at $483.6 million (Q1 2026), $414.2 million (Q4 2025), and $336.7 million (Q3 2025), per Business Quant data.